Statera Biopharma logo

Statera BiopharmaNASDAQ: STAB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 July 2021

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$5.47 K
-100%vs. 3y high
1%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Tue, 19 Nov 2024 14:30:00 GMT
$0.00$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

STAB Latest News

Correction: BNP Paribas Primary New Issues: Post-Stab - No STAB Notice - Webuild Spa
globenewswire.com23 October 2024 Sentiment: NEUTRAL

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice
globenewswire.com23 October 2024 Sentiment: NEUTRAL

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB Notice - LION/POLARIS (PICARD)
globenewswire.com23 October 2024 Sentiment: NEUTRAL

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. LION/POLARIS LUX 4 S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB Notice - ACCORINVEST GROUP S.A
globenewswire.com23 October 2024 Sentiment: NEUTRAL

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ACCORINVEST GROUP S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB - ILIAD S.A
globenewswire.com23 October 2024 Sentiment: NEUTRAL

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ILIAD S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Sammontana No STAB Notice
globenewswire.com07 October 2024 Sentiment: NEUTRAL

7TH October 2024   Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. SAMMONTANA ITALIA S.p.A.

BNP Paribas Primary New Issues: STAB Notice
globenewswire.com02 October 2024 Sentiment: NEUTRAL

02/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. CMA CGM Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated [01/10/2024]] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice - NO STAB - AZELIS Finance NV
globenewswire.com17 September 2024 Sentiment: NEUTRAL

[17.09.2024] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [AZELIS FINANCE NV] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated [11.09.2024] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice - NO STAB - Crown European Holdings S.A
globenewswire.com31 July 2024 Sentiment: NEUTRAL

[31/07/2024] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [Crown European Holdings S.A] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated [30/07/2024] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice - NO STAB - RINO MASTROTTO S.P.A
globenewswire.com12 July 2024 Sentiment: NEGATIVE

[12/7/24] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [RINO MASTROTTO GROUP S.P.A] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated 11/7/2014 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

What type of business is Statera Biopharma?

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. operates as a subsidiary of Biostax Corp.

What sector is Statera Biopharma in?

Statera Biopharma is in the Healthcare sector

What industry is Statera Biopharma in?

Statera Biopharma is in the Biotechnology industry

What country is Statera Biopharma from?

Statera Biopharma is headquartered in United States

When did Statera Biopharma go public?

Statera Biopharma initial public offering (IPO) was on 28 July 2021

What is Statera Biopharma website?

https://www.staterabiopharma.com

Is Statera Biopharma in the S&P 500?

No, Statera Biopharma is not included in the S&P 500 index

Is Statera Biopharma in the NASDAQ 100?

No, Statera Biopharma is not included in the NASDAQ 100 index

Is Statera Biopharma in the Dow Jones?

No, Statera Biopharma is not included in the Dow Jones index

When was Statera Biopharma the previous earnings report?

No data

When does Statera Biopharma earnings report?

The next expected earnings date for Statera Biopharma is 29 November 2024